Ashutosh Tripathi

About

I am a Senior Postdoctoral Fellow at the Center for Global Infectious Disease Research, part of the Seattle Children’s Research Institute. My research focuses on understanding how infectious disease pathogens, such as Mycobacterium tuberculosis, adapt to hostile host environments, metabolic limitations, and antibiotic pressure. I specialize in applying advanced molecular and metabolic approaches, including CRISPR interference, metabolomics, Seahorse bioenergetics profiling, macrophage infection models, and next-generation drug screening technologies like NanoBRET and NanoBiT. Prior to my current role, I completed postdoctoral training at the Indian Institute of Science (IISc), Bangalore, where I investigated iron-sulfur cluster biogenesis systems. My peer-reviewed work has been featured in leading journals, including PLoS Pathogens, Redox Biology, and Antimicrobial Agents and Chemotherapy, contributing key insights into bacterial persistence and stress response mechanisms.

Employment

• Seattle Children's Hospital Post Doctoral Fellow
  2023 - 2027
• The University of Texas Health Science Center at Tyler Postdoc
  2022 - 2023
• Indian Institute of Science Post Doctoral Fellow
  2018 - 2022

Education

• Central Drug Research Institute Ph.D.
  2011 - 2016

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Inorganic sulfate transport by the Mycobacterium tuberculosis PE22/PPE36 complex
  2026 DOI: 10.64898/2026.06.04.730267
  +Save
• Navigating the COVID-19 Treatment Landscape: Efficacy and Side-Effects of Current Therapies against SARS-CoV-2.
  Current HIV research 2025 DOI: 10.2174/011570162x338375250414114957
  +Save
• Intracellular peroxynitrite perturbs redox balance, bioenergetics, and Fe-S cluster homeostasis in Mycobacterium tuberculosis.
  Redox biology 2024 DOI: 10.1016/j.redox.2024.103285
  +Save
• Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species
  Antimicrobial Agents and Chemotherapy 2022 DOI: 10.1128/aac.00592-22
  +Save
• Mycobacterium tuberculosis requires SufT for Fe-S cluster maturation, metabolism, and survival in vivo.
  PLoS pathogens 2022 DOI: 10.1371/journal.ppat.1010475
  +Save
• A new blood-based RNA signature (R9), for monitoring effectiveness of tuberculosis treatment in a South Indian longitudinal cohort
  iScience 2022 DOI: 10.1016/j.isci.2022.103745
  +Save
• Mycobacterium tuberculosis SufR responds to nitric oxide via its 4Fe–4S cluster and regulates Fe–S cluster biogenesis for persistence in mice
  Redox Biology 2021 DOI: 10.1016/j.redox.2021.102062
  +Save
• Mycobacterium bovis sigF mutant exhibits altered surface phenotype and compromised pathogenesis.
  Tuberculosis (Edinburgh, Scotland) 2019 DOI: 10.1016/j.tube.2019.07.006
  +Save
• hsa-let-7b-5p facilitates Mycobacterium tuberculosis survival in THP-1 human macrophages by Fas downregulation.
  FEMS microbiology letters 2018 DOI: 10.1093/femsle/fny040
  +Save
• Identification and characterization of Rv0494: a fatty acid-responsive protein of the GntR/FadR family from Mycobacterium tuberculosis.
  Microbiology (Reading, England) 2013 DOI: 10.1099/mic.0.066654-0
  +Save